| Title: |
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy |
| Authors: |
Redondo-Muñoz, Marta; Rodríguez Baena, Francisco Javier; Aldaz, Paula; Caballé-Mestres, Adrià; Moncho-Amor, Verónica; Otaegi-Ugartemendia, Maddalen; Carrasco García, Estefanía; Olias Arjona, Ana; Lasheras-Otero, Irene; Santamaria, Eva; Bocanegra, Ana; Chocarro, Luisa; Grier, Abby; Dzieciatkowska M, Monika; Bigas, Claudia; Martin, Josefina; Urdiroz-Urricelqui, Uxue; Marzo, Florencio; SANTAMARIA, ENRIQUE; Kochan, Grazyna; Escors, David; Larrayoz, Ignacio M; Heyn, Holger; D’Alessandro, Angelo; Stephan-Otto Attolini, Camille; matheu, ander; Wellbrock, Claudia; Aznar Benitah, Salvador; Sanchez-Laorden, Berta; Arozarena, Imanol |
| Contributors: |
Institutos de la UMH::Instituto de Neurociencias |
| Publisher Information: |
Nature Portfolio |
| Publication Year: |
2023 |
| Collection: |
RediUMH (Universidad Miguel Hernández) |
| Description: |
Resistance of melanoma to targeted therapy and immunotherapy is linked to metabolic rewiring. Here, we show that increased fatty acid oxidation (FAO) during prolonged BRAF inhibitor (BRAFi) treatment contributes to acquired therapy resistance in mice. Targeting FAO using the US Food and Drug Administration-approved and European Medicines Agency-approved anti-anginal drug ranolazine (RANO) delays tumour recurrence with acquired BRAFi resistance. Single-cell RNA-sequencing analysis reveals that RANO diminishes the abundance of the therapy-resistant NGFRhi neural crest stem cell subpopulation. Moreover, by rewiring the methionine salvage pathway, RANO enhances melanoma immunogenicity through increased antigen presentation and interferon signalling. Combination of RANO with anti-PD-L1 antibodies strongly improves survival by increasing antitumour immune responses. Altogether, we show that RANO increases the efficacy of targeted melanoma therapy through its effects on FAO and the methionine salvage pathway. Importantly, our study suggests that RANO could sensitize BRAFi-resistant tumours to immunotherapy. Since RANO has very mild side-effects, it might constitute a therapeutic option to improve the two main strategies currently used to treat metastatic melanoma. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://doi.org/10.1038/s42255-023-00861-4; https://hdl.handle.net/11000/30784 |
| Availability: |
https://hdl.handle.net/11000/30784 |
| Rights: |
info:eu-repo/semantics/openAccess ; Attribution-NonCommercial-NoDerivatives 4.0 Internacional ; http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.83FBB953 |
| Database: |
BASE |